Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy
Executive Summary
Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.
You may also be interested in...
Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will likely need to dovetail with President Trump’s agenda to advance.
Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.
Part B Payment Model Indexing Commercial Discounts Proposed By Genentech
Approach offered as alternative to more disruptive changes to Part B's existing buy-and-bill system; more aggressive proposals include new iteration of competitive acquisition program and moving Part B drug coverage to Part D.